Vibe Bio
Vibe Bio operates VibeOne, an AI-powered decision infrastructure platform that helps biopharma business development teams identify and evaluate drug assets globally, alongside a venture fund backing biotechs developing rare disease therapeutics.
- Company typePrivate
- Founded2021
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Vibe Bio does
Vibe Bio is a Boston-based, remote-first company founded in 2021 by Alok Tayi, PhD, that operates a dual business combining an AI-powered SaaS platform for biopharma business development with a venture fund targeting rare and overlooked diseases. The company's core product, the VibeOne platform, uses natural language processing, predictive analytics, generative AI reasoning, and process automation to aggregate scientific, clinical, regulatory, and market data across more than 40 languages, then delivers expert-validated analyses that support go/no-go decisions on drug in-licensing and portfolio strategy for biopharma BD teams. Reported platform outcomes include 8x faster asset diligence, a 75% reduction in subject-matter expert workload, and 50% more assets identified globally, with particular emphasis on coverage of programs in China, Japan, and Korea.
The company sells VibeOne through a direct enterprise field-sales motion with quote-based annual subscription pricing and a "Request a demo" entry point, targeting Chief Strategy Officers and Business Development & Licensing executives at pharmaceutical and large biotech firms, as well as non-profit accelerators such as Orphan Therapeutics Accelerator. Complementing the platform business, Vibe Bio runs a venture fund that invests in and supports biotech founders developing platform technologies and therapeutics for rare diseases; disclosed portfolio companies include Eigen Therapeutics (priming therapies for cancer), Granata Bio (reproductive health, including its 2025 expansion to incorporate Oviva Therapeutics), and Cellular Intelligence (an AI-native TechBio that has raised over $60M from Khosla Ventures, CZI, SciFi VC, and AMD Ventures). The company also launches dedicated biotechs in partnership with patient foundations such as Chelsea's Hope and NF2 BioSolutions.
Vibe Bio launched publicly in June 2022 with $12M in seed financing led by Initialized Capital, alongside 6th Man Ventures, AlleyCorp, Arkitekt Ventures, Koa Labs, Lerer Hippeau, and Undeterred Capital. The company is registered as Vibe Biotechnology Inc. in Massachusetts, maintains a Scientific Advisory Board that includes Samuel Stupp (Northwestern), Kanya Rajangam (Senti Bio), and Yael Weiss (Mahzi Therapeutics), and continues to add roles across marketing, drug development, and engineering as it scales.
Vibe Bio firmographics
Firmographics- Name
- Vibe Bio
- Legal name
- Vibe Biotechnology Inc.
- Website
- https://vibebio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Vibe Bio operates VibeOne, an AI-powered decision infrastructure platform that helps biopharma business development teams identify and evaluate drug assets globally, alongside a venture fund backing biotechs developing rare disease therapeutics.
- Ownership category
- akta.pro rank
Vibe Bio industry classification
Industry- Product category
- Biopharma AI Analytics Platform
- NAICS
- Other Scientific and Technical Consulting Services (54169), Computer Systems Design and Related Services (54151)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Regulatory Information Management (RIM) & Submission Publishing Software (HLAGAJAL)
Keywords
Where Vibe Bio is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Vibe Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- VibeOne AI Platform - Business Development Services: Expert-guided AI analysis platform for biopharma business development and licensing teams. The platform supports pipeline decisions with speed and discipline through subscription-based access to AI-powered asset identification, evaluation, and prioritization services.
- Venture Fund Investment Returns: Vibe Bio invests in founders developing platform technologies and therapeutics for rare and overlooked diseases. The venture fund generates returns through equity investments in portfolio companies including Eigen Therapeutics, Granata Bio, and Cellular Intelligence.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription model with custom pricing |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
Vibe Bio product offering
Product offeringCore offering
Vibe Bio operates the VibeOne AI platform, an enterprise decision infrastructure that helps biopharma business development and licensing teams identify, evaluate, and prioritize drug assets faster and with greater consistency. The platform aggregates global scientific, clinical, regulatory, and market data and applies AI reasoning combined with expert validation to deliver custom reports supporting go/no-go pipeline decisions. Complementing the platform, Vibe Bio operates a venture fund that invests in founders developing therapeutics for rare and overlooked diseases.
Product overview
Vibe Bio operates as a dual-entity company offering both an AI-powered SaaS platform and a venture fund. The core product is the VibeOne Platform—an AI decision infrastructure for biopharma business development that provides search, evaluation, and due diligence capabilities. This platform includes the VibeOne AI Analysis service (expert-guided AI analysis with data aggregation, pattern detection, and custom reporting) and the VibeOne Search & Evaluation module (for scanning drug landscapes and tracking competitive markets). Complementing the platform business, Vibe Bio operates a Venture Fund that invests in biotech founders targeting rare and overlooked diseases, applying the same VibeOne AI capabilities to guide portfolio decisions. The company was founded in 2021-2022 and is headquartered in Boston, MA.
Differentiator
Problem solved
Functional benefit
Products and services
- VibeOne Platform AI-powered decision infrastructure for biopharma business development that enables faster, better go/no-go pipeline decisions through automated asset identification, evaluation, and prioritization across indications, stages, and geographies. Sold via enterprise annual subscriptions to biopharma BD and licensing teams.
- Vibe Bio Venture Fund Investment arm that provides funding and AI-driven due diligence and strategic support to biotech founders developing platform technologies and therapeutics, with particular emphasis on rare or overlooked diseases. Portfolio companies include Eigen Therapeutics, Granata Bio, and Cellular Intelligence.
Quantifiable outcome
- 8x faster asset diligence with curated, aggregated, and centralized data
- +3 more outcomes
Companies that use Vibe Bio
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Vibe Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature4 records
Vibe Bio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Chelsea's HopeminorFoundation focused on Lafora disease, a fatal form of progressive myoclonus epilepsy. Vibe Bio launched a biotech company in partnership with Chelsea's Hope.
- InciteminorIncite partnered with Vibe Bio to accelerate sarcoma drug discovery with unbiased ranking and AI-powered compound analysis. Vibe Bio provides AI analytics services for Incite's rare disease drug search and evaluation processes.
- Orphan Therapeutics AcceleratorcoreNon-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions. Uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy. OTXL announced foundational partnerships with rare disease-focused global biotech and pharmaceutical companies.
- NF2 BioSolutionsminorOrganization hoping to accelerate a gene therapy for neurofibromatosis Type 2. Vibe Bio launched a biotech company in partnership with NF2 BioSolutions.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Vibe Bio competitors and assessment
Company assessmentDirect peers
- InveniAI: AI-powered platform focused on pharma asset identification, BD, and in-licensing signal generation. Most direct head-to-head competitor to VibeOne's use case of using AI to surface and prioritize drug programs for biopharma BD teams.
- DealForma: Biopharma deal intelligence and BD workflow platform used by pharma business development teams to source, evaluate, and track in-licensing opportunities. Comparable in target buyer (biopharma BD) and workflow (asset diligence) to VibeOne.
Broad incumbents
- Clarivate: Large established provider of pharma intelligence, competitive intelligence, and BD analytics (e.g., Cortellis, Decision Resources Group). Competes with VibeOne for biopharma BD budgets at the portfolio strategy level, though as part of a much broader portfolio.
- IQVIA: Global life sciences services and data analytics incumbent offering BD support, pipeline intelligence, and commercial diligence. Overlaps with VibeOne in BD analytics for biopharma but as one capability within a comprehensive CRO/data-services franchise.
- Citeline (Pharma Intelligence): Pharma pipeline, clinical trial, and deal intelligence provider (Pharmaprojects, Trialtrove). Directly comparable on the drug-asset visibility and pipeline benchmarking that VibeOne delivers, but as a content/data incumbent rather than an AI-native platform.
Emerging players
- Recursion Pharmaceuticals: AI-native biotech combining proprietary data generation with ML for drug discovery and BD. Comparable on the AI-for-biopharma thesis and as a potential VibeOne customer/partner, though focused on internal pipeline rather than BD analytics as a service.
- Insitro: AI-driven drug discovery company applying ML to phenotypic and omics data. Comparable on AI-meets-biopharma positioning and target buyer overlap, though focused on its own pipeline development rather than BD decision infrastructure.
- Benchling: Cloud platform for life science R&D data and workflows. Adjacent rather than direct — same buyer (biopharma) but different use case (lab informatics vs. BD diligence) — and a plausible partner or substitute in a customer's AI/data stack.
- Owkin: AI platform applied to clinical research and drug development for biopharma partners. Comparable on AI-platform-for-biopharma model and enterprise GTM, though focused on clinical/ translational analytics rather than BD asset evaluation.
- CytoReason: AI model of the human immune system for pharma R&D and pipeline prioritization. Comparable in selling AI-driven decision infrastructure to biopharma R&D and BD leadership, though focused on biological mechanism rather than deal sourcing.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Vibe Bio social profiles
Digital presenceVibe Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vibe Bio leadership team
Management profileNumber of profiles
Profiles11 records
Vibe Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vibe Bio M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vibe Bio
What does Vibe Bio do?
Vibe Bio operates the VibeOne AI platform, an enterprise decision infrastructure that helps biopharma business development and licensing teams identify, evaluate, and prioritize drug assets faster and with greater consistency. The platform aggregates global scientific, clinical, regulatory, and market data and applies AI reasoning combined with expert validation to deliver custom reports supporting go/no-go pipeline decisions. Complementing the platform, Vibe Bio operates a venture fund that invests in founders developing therapeutics for rare and overlooked diseases.
Is Vibe Bio a public or private company?
Vibe Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vibe Bio founded?
Vibe Bio was founded in 2021. It employs 1 to 10 people.
Where is Vibe Bio based?
Vibe Bio is headquartered in Boston, United States, in the North America region.
How does Vibe Bio make money?
Two revenue lines are on record. VibeOne AI Platform - Business Development Services are the primary driver. The others are venture Fund Investment Returns.
Who are Vibe Bio's main competitors?
Direct peers on record are InveniAI and DealForma. Broad incumbents are Clarivate, IQVIA and Citeline (Pharma Intelligence). Emerging players are Recursion Pharmaceuticals, Insitro, Benchling, Owkin and CytoReason.
Does Vibe Bio have an API?
No public API is recorded for Vibe Bio.
What industry is Vibe Bio in?
Vibe Bio's product category is Biopharma AI Analytics Platform. Its primary akta.pro industry code is HLAGAJAL, Regulatory Information Management (RIM) & Submission Publishing Software. Its NAICS code is 54169 and its SIC code is 8731.